CDK4/6抑制剂治疗HR+/HER2?晚期乳腺癌的临床研究进展  

Advances in Clinical Research on the CDK4/6 Inhibitors for HR+/HER2? Advanced Breast Cancer

作　　者：李周娟 赵久达[2] 

机构地区：[1]青海大学研究生院,青海 西宁 [2]青海大学附属医院乳腺疾病诊疗中心,青海 西宁

出　　处：《临床医学进展》2024年第3期458-466,共9页Advances in Clinical Medicine

摘　　要：激素受体(HR)阳性,人表皮生长因子受体2 (HER-2)阴性乳腺癌在所有乳腺癌中占比>70%。内分泌治疗是HR+/HER2−乳腺癌的主要治疗方式,但不可避免的会产生耐药。细胞周期蛋白依赖性激酶(CDK) 4/6抑制剂是逆转内分泌治疗耐药的有效药物。这类分子靶向药物为HR+/HER2−乳腺癌患者的临床治疗模式带来变革性的突破。中国已上市的CDK4/6抑制剂包括瑞波西利、哌柏西利、阿贝西利和达尔西利。对于HR+/HER2−晚期乳腺癌,CDK4/6抑制剂联合内分泌治疗已经成为标准方案,能够延长患者的生存。本综述主要阐述四种CDK4/6抑制剂在HR+/HER2−晚期乳腺癌中的疗效、适应症、药物介绍及不良反应的管理,为临床决策提供参考,延长患者生存和提高生活质量。Hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER-2)-negative breast cancer accounts for >70% of all breast cancers. Endocrine therapy is the mainstay of treatment for HR+/HER2− breast cancer, but inevitably results in drug resistance. Cell cycle pro-tein-dependent kinase (CDK) 4/6 inhibitors are effective agents for reversing resistance to endo-crine therapy. These molecularly targeted drugs have brought about a transformative break-through in the clinical treatment paradigm for HR+/HER2− breast cancer patients. CDK4/6 inhib-itors that have been marketed in China include Ribociclib, Palbociclib, Abemaciclib and Dalpiciclib. For HR+/HER2− advanced breast cancer, CDK4/6 inhibitors in combination with endocrine therapy have become a standard regimen that can prolong patient survival. This review focuses on the efficacy, indications, safety and drug-drug interactions of four CDK4/6 inhibitors in HR+/HER2− advanced breast cancer, informing clinical decision-making, prolonging patient survival and improving quality of life.

关 键 词：乳腺癌 细胞周期蛋白依赖性激酶4/6抑制剂 激素受体 疗效 安全性 

分 类 号：R73[医药卫生—肿瘤]